Previous close | 1.4500 |
Open | 2.3000 |
Bid | 1.8800 |
Ask | 2.5600 |
Strike | 1,100.00 |
Expiry date | 2024-09-20 |
Day's range | 2.0400 - 2.3000 |
Contract range | N/A |
Volume | |
Open interest | 424 |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.